KR960701096A - 그룹 B 스트렙토코커스의 많은 균주들에 대한 면역성을 제공하는 세포 표면 단백질인 Rib 단백질, 그 단백질의 정제방법, 시약키트 및 제약조성물(PROTEIN RIB. A CELL SURFACE PROTEIN THAT CONFERS IMMUNITY TO MANY STRAINS OF THE GROUP B STREPTOCOCCUS; PROCESS FOR PURIFICATION OF THE PROTEIN, PEAGENT KIT AND PHARMACEUTICAL COMPOSITION) - Google Patents
그룹 B 스트렙토코커스의 많은 균주들에 대한 면역성을 제공하는 세포 표면 단백질인 Rib 단백질, 그 단백질의 정제방법, 시약키트 및 제약조성물(PROTEIN RIB. A CELL SURFACE PROTEIN THAT CONFERS IMMUNITY TO MANY STRAINS OF THE GROUP B STREPTOCOCCUS; PROCESS FOR PURIFICATION OF THE PROTEIN, PEAGENT KIT AND PHARMACEUTICAL COMPOSITION) Download PDFInfo
- Publication number
- KR960701096A KR960701096A KR1019950703989A KR19950703989A KR960701096A KR 960701096 A KR960701096 A KR 960701096A KR 1019950703989 A KR1019950703989 A KR 1019950703989A KR 19950703989 A KR19950703989 A KR 19950703989A KR 960701096 A KR960701096 A KR 960701096A
- Authority
- KR
- South Korea
- Prior art keywords
- protein
- rib
- streptococcus
- vector
- cell surface
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 32
- 241000193990 Streptococcus sp. 'group B' Species 0.000 title claims abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract 6
- 230000036039 immunity Effects 0.000 title claims abstract 4
- 238000000034 method Methods 0.000 title claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 4
- 241000194017 Streptococcus Species 0.000 title claims 2
- 102000018697 Membrane Proteins Human genes 0.000 title 2
- 108010052285 Membrane Proteins Proteins 0.000 title 2
- 238000000746 purification Methods 0.000 title 1
- 239000012634 fragment Substances 0.000 claims abstract 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 9
- 230000001681 protective effect Effects 0.000 claims abstract 3
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- 102000004142 Trypsin Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- 239000012588 trypsin Substances 0.000 claims description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 claims description 2
- 241000701959 Escherichia virus Lambda Species 0.000 claims 6
- 238000000926 separation method Methods 0.000 claims 3
- 239000006228 supernatant Substances 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 238000002523 gelfiltration Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 많은 그룹 B Streptococcus균주들, 특히 혈청형Ⅲ인 것들의 감염에 대한 보호면역성을 제공하는 Rib으로 표시되는 새로운 단백질 및 그것의 소단편, 다중체 또는 변이체에 관한 것이다.
본 발명은 이 단백질의 정제 방법, 매우 특이적인 항체의 제조방법, 시약키트, 이 단백질을 암호화 하는 DNA서열, 이 단백질 또는 그것의 단편이나 변이체를 함유하는 제약조성물을 포함한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 4가지 주요 혈청형을 나타내는 그룹 B Streptococcus균주로부터 제조한 주출물의 웨턴 블롯(Western blot)분석을 보여준다(타입 Ⅰ a : 균주 A909 : 타입 Ⅰb:SB35:타입Ⅱ :B1284: 타입Ⅲ:BS300. 면역 블롯에서 보여지는 것처럼 타입 Ⅰa 및 Ⅰb의 균주는 알파 및 베타 단백질을 발현하고, 염색된 겔에서 이 단백질의 위치는 화살표로 표시된다.좌측에 나타낸 분자량 마커의 단위는 KD이다.
제5도는 트립신 또는 펩신으로 처린 정제된 알파, 베타, 및 Rib단백질의 SDS-PAGE 분석을 보여준다. 트립신 처리는 pH7.5에서 수행되었고, 펩신처리는 pH4.0에서 수행되었다.SDS-PAGE분석전에 샘플을 중화시켰다. 콘트롤은 트립신 또는 펩신을 포함하는 샘플과 동일한 방식으로 처리했지만 효소를 첨가하지 않았다. 그렇나 처리는 단백질의 분해를 야기하지 않았다. P=펩신 :T=트립신, 좌측에 나타낸 분자량 마커 단위는 KD이다.
Claims (17)
- (a)그룹 B STREPTOCOCCUS균주,특히 혈청형Ⅲ인 것들로부터 얻을 수 있고,b)트립신 및 펩신에 의한 분해에 비교적 저항성이 있고, c)SEQ ID NO : 1에 따른 N-말단 아미노산 서열 또는 그것과 적어도 90% 상동적인 서열을 갖고, 및 d)이 단백질을 발현하는 그룹 B STREPTOCOCCUS균주에 대해서 보호면역성을 제공하는 것을 특징으로 하는 Rib으로 표시되는 정제된 단백질, 및 보호면역성을 제공할 숭 있는 능력을 갖는 천연적으로 존재하거나 인공적으로 변형된 그것의 변이체, 소단편 및 다중체.
- 제1항에 있어서, 상기 균주는 BS 30 또는 BM 110이고 단백질은 SDS-PAGE에 의해 결정할 때 약 95KD의 겉보기 분자량을 갖는 것을 특징으로 하는 단백질.
- Rib단백질을 발현하는 STREPTOCOCCUS그룹 B균주를 배양하고, 배지 및/또는 미생물을 분리학, 세균을 효소 바람직하게는 뮤타노리신으로 분해시키고,프로테아제 억제인자를 선택적으로 첨가하고, 분해된 세균을 상징액으로부터 분리하고, Rib단백질을 상징액으로부터 추출하는 것을 특징으로 하는 Rib단백질의 분리방법.
- 제3항에 있어서, 단백질은 투석, 이온교환 크로마토그피에 의한 분리 및 겔여과에 의해 상징액으로부터 추출되는 것을 측징으로 하는 방법.
- 제1항에서 정의된 Rib단백질 및 그것의 변이체, 소단편 및 다중체에 매우 특이적인 항체.
- Rib단백질에 대한 항체의 검출을 위한 시약키트에 있어서,제1항에서 정의된 Rib단백질 또는 그것의 변이체, 소단편 및 다중체를 함유하는 것을 특징으로 하는 시약키트.
- Rib단백질의 검출을 위한 시약키트에 있어서, 제1항에서 정의된 단백질에 특이적인 항체, 및 선택적으로 표준물로서 Rib단백질 및 그것의 변이체, 소단편 및/또는 다중체를 함유하는 것을 특징으로하는 시약키트.
- 제1항에 정의된 Rib단백질 또는 그것의 변이체, 소단편 또는 다중체를 암호화 하는 DNA서열을 포함하는 벡터.
- 제8항에 있어서, Rib단백질을 암호화하는 벡터의 DNA서열은 수탁번호 DSM 9039를 갖는 파지 람다 Rib 1-3의 대응 DNA서열 중 어느 것과 본질적으로 동일한 것을 특징으로 하는 벡터.
- 제8항에 있어서, Rib 단백질을 암호화하는 벡터의 DNA서열은 수탁번호 DSM 9040을 갖는 파지 람다 Rib 1-5의 대응 DNA서열 중 어느 것과 본질적으로 동일한 것을 특징으로 하는 벡터.
- 제8항에 있어서, Rib 단백질을 암호화하는 벡터의 DNA서열은 수탁번호 DSM 9041을 갖는 파지 람다 Rib 1-7의 대응 DNA서열 중 어느 것과 본질적으로 동일한 것을 특징으로 하는 벡터.
- 수탁번호 DSM 9039을 갖는 파지 람다 Rib 1-3.
- 수탁번호 DSM 9040을 갖는 파지 람다 Rib 1-5.
- 수탁번호 DSM 9041을 갖는 파지 람다 Rib 1-7.
- 제8항에서 정의된 벡터로부터 얻을 수 있는, Rib 단백질 또는 그것의 변이체, 소단편 또는 다중체를 암호화하는 DNA서열.
- 제1항에서 정의된 Rib 단백질 또는 그것의 변이체, 소단편 또는 다중체를 함유하는 제약조성물에서, 상기 조성물이 추가로 제약학적으로 허용가능한 보조약 또는 부형제를 함유하는 것을 특징으로 하는 조성물.
- 제1항에서 정의된 Rib 단백질 또는 그것의 변이체, 소단편 또는 다중체를 함유하는 백신에서, 상기 백신이 추가로 제약학적으로 허용가능한 보조약 또는 부형제를 함유하는 것을 특징으로 하는 백신.※참고사항: 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SEPCT/SE93/00234 | 1993-03-19 | ||
| SE9300234 | 1993-03-19 | ||
| PCT/SE1994/000246 WO1994021685A1 (en) | 1993-03-19 | 1994-03-21 | Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR960701096A true KR960701096A (ko) | 1996-02-24 |
| KR100331358B1 KR100331358B1 (ko) | 2002-08-13 |
Family
ID=20388669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950703989A KR100331358B1 (ko) | 1993-03-19 | 1994-03-21 | 그룹B스트렙토코커스의많은균주들에대한면역성을제공하는세포표면단백질인Rib단백질,그단백질의정제방법,시약키트및제약조성물 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5869064A (ko) |
| EP (1) | EP0656014B1 (ko) |
| JP (1) | JP3976334B2 (ko) |
| KR (1) | KR100331358B1 (ko) |
| CN (1) | CN1046291C (ko) |
| AT (1) | ATE240351T1 (ko) |
| CA (1) | CA2158658A1 (ko) |
| DE (1) | DE69432658T2 (ko) |
| DK (1) | DK0656014T3 (ko) |
| ES (1) | ES2194024T3 (ko) |
| HK (1) | HK1008825A1 (ko) |
| HU (1) | HU217582B (ko) |
| NZ (1) | NZ263275A (ko) |
| PT (1) | PT656014E (ko) |
| SG (1) | SG47049A1 (ko) |
| SI (1) | SI0656014T1 (ko) |
| WO (1) | WO1994021685A1 (ko) |
| ZA (1) | ZA941958B (ko) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015889A (en) | 1993-03-19 | 2000-01-18 | Gunnar Lindahl | Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition |
| JP4637350B2 (ja) | 1998-02-20 | 2011-02-23 | アイディ・バイオメディカル・コーポレイション | グループｂ連鎖球菌抗原 |
| KR100818815B1 (ko) | 1998-12-22 | 2008-04-01 | 마이크로싸이언스 리미티드 | 외표면 단백질들, 그들의 유전자들 및 그들의 사용 |
| US6890539B2 (en) | 1998-12-22 | 2005-05-10 | Microscience, Ltd. | Genes and proteins, and their use |
| DK1141308T3 (da) * | 1998-12-22 | 2007-06-04 | Microscience Ltd | Gruppe B streptococcus proteiner og deres anvendelse |
| CZ303675B6 (cs) * | 1998-12-23 | 2013-02-27 | Id Biomedical Corporation Of Quebec | Izolovaný polynukleotid, vektor, hostitelská bunka, zpusob produkce, izolovaný polypeptid, chimérový polypeptid, vakcinacní prostredek a pouzití |
| US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
| GB9910375D0 (en) | 1999-05-05 | 1999-06-30 | Lindahl Gunnar | Vaccine composition |
| DE60221126T2 (de) * | 2001-05-31 | 2008-03-13 | Fuso Pharmaceutical Industries, Ltd. | Verbessertes verfahren zum nachweis und zur identifizierung eines eine infektion verursachenden mikroorganismus |
| EP1795594A3 (en) * | 2001-05-31 | 2008-04-02 | Fuso Pharmaceutical Industries, Ltd. | Method of evaluating the function of phagocyte and utilization thereof |
| AU2003203097C1 (en) * | 2002-02-11 | 2010-02-04 | Id Biomedical Corporation | Group B streptococcus antigen |
| JP2008530021A (ja) * | 2005-02-08 | 2008-08-07 | アイディー バイオメディカル コーポレイション オブ ケベック シー．オー．ビー． アズ グラクソスミスクライン バイオロジカルズ ノース アメリカ | 医薬組成物 |
| RU2487890C2 (ru) * | 2007-04-16 | 2013-07-20 | МинерваКС Апс | Слитый белок, способный индуцировать защитный иммунитет против стрептококка группы в, и вакцина, содержащая такой белок |
| RU2757426C2 (ru) | 2015-10-21 | 2021-10-15 | МинерваКС Апс | Иммунногенный слитый белок |
| US10888610B2 (en) | 2015-12-30 | 2021-01-12 | Minerv Ax Aps | Immunogenic complex for eliciting protective immunity against group b streptococcus |
| WO2018229708A1 (en) | 2017-06-16 | 2018-12-20 | Glaxosmithkline Biologicals Sa | Method of treatment |
| CN114728051A (zh) | 2019-11-22 | 2022-07-08 | 葛兰素史克生物有限公司 | 细菌糖糖缀合物疫苗的剂量和施用 |
| EP4066854A1 (en) | 2021-03-29 | 2022-10-05 | MinervaX | Immunogenic fusion protein |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5302386A (en) * | 1986-04-16 | 1994-04-12 | Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines and methods of manufacture |
| US4772584A (en) * | 1986-05-23 | 1988-09-20 | Cleary Paul P | Inhibitor of C5a-mediated chemotaxis |
| EP0367890A1 (en) * | 1988-11-11 | 1990-05-16 | HighTech Receptor AB | Protein Arp, with immunoglobulin A binding activity, cloning and expression thereof |
| IL95578A (en) * | 1989-09-15 | 1998-08-16 | Gen Hospital Corp | A vaccine made from polysaccharide and protein |
| US5648241A (en) * | 1989-09-15 | 1997-07-15 | The General Hospital Corporation | Conjugate vaccine against group B streptococcus |
| EP0577723A1 (en) * | 1991-03-29 | 1994-01-12 | FAULMANN, Ervin | METHOD FOR PRODUCTION OF AN IgA BINDING PROTEIN DERIVED FROM GROUP B STREPTOCOCCI |
-
1994
- 1994-03-21 SG SG1996004387A patent/SG47049A1/en unknown
- 1994-03-21 PT PT94911348T patent/PT656014E/pt unknown
- 1994-03-21 KR KR1019950703989A patent/KR100331358B1/ko not_active IP Right Cessation
- 1994-03-21 HU HU9501993A patent/HU217582B/hu not_active IP Right Cessation
- 1994-03-21 WO PCT/SE1994/000246 patent/WO1994021685A1/en active IP Right Grant
- 1994-03-21 ES ES94911348T patent/ES2194024T3/es not_active Expired - Lifetime
- 1994-03-21 JP JP52094694A patent/JP3976334B2/ja not_active Expired - Fee Related
- 1994-03-21 ZA ZA941958A patent/ZA941958B/xx unknown
- 1994-03-21 SI SI9430453T patent/SI0656014T1/xx unknown
- 1994-03-21 CN CN94191519A patent/CN1046291C/zh not_active Expired - Fee Related
- 1994-03-21 AT AT94911348T patent/ATE240351T1/de not_active IP Right Cessation
- 1994-03-21 DE DE69432658T patent/DE69432658T2/de not_active Expired - Lifetime
- 1994-03-21 CA CA002158658A patent/CA2158658A1/en not_active Abandoned
- 1994-03-21 NZ NZ263275A patent/NZ263275A/en not_active IP Right Cessation
- 1994-03-21 DK DK94911348T patent/DK0656014T3/da active
- 1994-03-21 EP EP94911348A patent/EP0656014B1/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/487,675 patent/US5869064A/en not_active Expired - Fee Related
-
1998
- 1998-07-29 HK HK98109536A patent/HK1008825A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HU9501993D0 (en) | 1995-08-28 |
| ZA941958B (en) | 1995-01-27 |
| CN1119442A (zh) | 1996-03-27 |
| ES2194024T3 (es) | 2003-11-16 |
| CA2158658A1 (en) | 1994-09-29 |
| KR100331358B1 (ko) | 2002-08-13 |
| EP0656014A1 (en) | 1995-06-07 |
| HU217582B (hu) | 2000-02-28 |
| JP3976334B2 (ja) | 2007-09-19 |
| US5869064A (en) | 1999-02-09 |
| EP0656014B1 (en) | 2003-05-14 |
| SI0656014T1 (en) | 2003-12-31 |
| DE69432658T2 (de) | 2004-04-08 |
| NZ263275A (en) | 1997-07-27 |
| PT656014E (pt) | 2003-09-30 |
| HUT72841A (en) | 1996-05-28 |
| HK1008825A1 (en) | 1999-05-21 |
| CN1046291C (zh) | 1999-11-10 |
| WO1994021685A1 (en) | 1994-09-29 |
| AU6389194A (en) | 1994-10-11 |
| SG47049A1 (en) | 1998-03-20 |
| AU681130B2 (en) | 1997-08-21 |
| JPH09500092A (ja) | 1997-01-07 |
| ATE240351T1 (de) | 2003-05-15 |
| DK0656014T3 (da) | 2003-08-11 |
| DE69432658D1 (de) | 2003-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960701096A (ko) | 그룹 B 스트렙토코커스의 많은 균주들에 대한 면역성을 제공하는 세포 표면 단백질인 Rib 단백질, 그 단백질의 정제방법, 시약키트 및 제약조성물(PROTEIN RIB. A CELL SURFACE PROTEIN THAT CONFERS IMMUNITY TO MANY STRAINS OF THE GROUP B STREPTOCOCCUS; PROCESS FOR PURIFICATION OF THE PROTEIN, PEAGENT KIT AND PHARMACEUTICAL COMPOSITION) | |
| US5785971A (en) | Pertussis toxin and use in vaccines | |
| Kodaira et al. | The dnaX gene encodes the DNA polymerase III holoenzyme τ subunit, precursor of the γ subunit, the dnaZ gene product | |
| JP2703770B2 (ja) | 結合タンパク質に融合されたタンパク質の生産及びその精製 | |
| Pettersson | Structural proteins of adenoviruses: VI. On the antigenic determinants of the hexon | |
| Chu et al. | Cloning and sequence analysis of the muramidase-2 gene from Enterococcus hirae | |
| HU205386B (en) | Process for expressing cloned lysostaphin gene and for producing dna fragment containing the gene, expression vector and transformed host cell | |
| Frey et al. | Purification and partial characterization of a hemolysin produced by Actinobacillus pleuropneumoniae type strain 4074 | |
| Loomes et al. | Purification and characterisation of human immunoglobulin IgA1 and IgA2 isotypes from serum | |
| DE69434839D1 (de) | Transferrin-rezeptor gene von haemophilus | |
| Qiu et al. | Analysis of the specificity of bacterial immunoglobulin A (IgA) proteases by a comparative study of ape serum IgAs as substrates | |
| Fujii et al. | Characterization of bacteriophage nucleic acids obtained from Clostridium botulinum types C and D | |
| Moriishi et al. | Purification and characterization of ADP-ribosyltransferases (exoenzyme C3) of Clostridium botulinum type C and D strains | |
| Lytton et al. | Isolation and partial characterization of the reduction-modifiable protein of Neisseria gonorrhoeae. | |
| Aitken et al. | Amino and carboxy terminal sequences of the DNA-binding protein HU from the Cyanobacterium Synechocystis PCC 6701 (ATCC 27170) | |
| Schmidt et al. | Mitogenicity of M5 protein extracted from Streptococcus pyogenes cells is due to streptococcal pyrogenic exotoxin C and mitogenic factor MF | |
| Pugsley et al. | Comparison of colicins B-K260 and D-CA23: purification and characterization of the colicins and examination of colicin immunity in the producing strains | |
| Sagane et al. | Role of C-terminal region of HA-33 component of botulinum toxin in hemagglutination | |
| JPH06503706A (ja) | ＩｇＧ結合タンパク質 | |
| Tolson et al. | Expression of a nonagglutinating fimbria by Proteus mirabilis | |
| Gamazo et al. | Brucella group 3 outer membrane proteins contain a heat-modifiable protein | |
| RU2230325C2 (ru) | Способ приготовления очищенного препарата ботулинического токсина типа а | |
| EP0420894B1 (en) | Large scale method for purification of high purity heparinase | |
| McCardell et al. | Cloning, expression and characterization of the CHO cell elongating factor (Cef) from Vibrio cholerae O1 | |
| McBride et al. | Cloning of Bacteroides gingivalis surface antigens involved in adherence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| B701 | Decision to grant | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20100122 Year of fee payment: 9 |
|
| LAPS | Lapse due to unpaid annual fee |